Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19

Benzinga Newsdesk www.benzinga.com Positive 73.5%

Neg 0% Neu 0% Pos 73.5%

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $18 to $19.